Experimental Evaluation of the Impact of Gadolinium Orthovanadate Gdvo4:Eu3%2B Nanoparticles on the Carrageenan-Induced Intestinal Inflammation
Anton S. Tkachenko, Galina I. Gubina-Vakulyck, Vladimir K. Klochkov, Nataliya S. Kavok, Anatolii I. Onishchenko, Tatyana V. Gorbach, Oksana A. Nakonechna
zveřejněno: 18. 05. 2020
Aim: To evaluate the effects of orally administered gadolinium orthovanadate GdVO4:Eu3+ nanoparticles (VNPs) on the course of chronic carrageenan-induced intestinal inflammation. Methods: Samples of small intestinal tissue were collected from four groups of rats (intact, after administration of VNPs, with carrageenaninduced intestinal inflammation, with carrageenan-induced intestinal inflammation orally exposed to VNPs) to assess the intestinal morphology and HSP90α expression. Levels of seromucoid, C-reactive protein, TNF-α, IL-1β and IL-10 were determined in blood serum. Results: Oral exposure to VNPs was associated with neither elevation of inflammation markers in blood serum nor HSP90α overexpression in the small intestine, i.e. no toxic effects of VNPs were observed. Carrageenan-induced intestinal inflammation was accompanied by higher levels of TNF-α and IL-1β, as well as HSP90α upregulation in the intestinal mucosa, compared with controls. Administration of VNPs to rats with enteritis did not lead to statistically significant changes in concentrations of circulating pro-inflammatory cytokines with the trend towards their increase. Conclusion: No adverse effects were observed in rats orally exposed to VNPs at a dose of 20 μg/kg during two weeks. Using the experimental model of carrageenan-induced enteritis, it was demonstrated that VNPs at the dose used in our study did not affect the course of intestinal inflammation.
Klíčová slova: nanoparticles; intestinal inflammation; HSP90α; rats; carrageenan
Experimental Evaluation of the Impact of Gadolinium Orthovanadate Gdvo4:Eu3%2B Nanoparticles on the Carrageenan-Induced Intestinal Inflammation is licensed under a Creative Commons Attribution 4.0 International License.